

Refine Search

Search Results -

| Term | Documents |
|--|-----------|
| (6 NOT 3).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD. | 77 |
| (L6 NOT L3).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD. | 77 |

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L7

Refine Search

Recall Text



Clear

Interrupt

Search History

DATE: Monday, August 29, 2005 [Printable Copy](#) [Create Case](#)

Set Name Query
 side by side

Hit Count **Set Name**
 result set

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES;
 OP=AND

| | | | |
|-----------|--|-------|-----------|
| <u>L7</u> | L6 not L3 | 77 | <u>L7</u> |
| <u>L6</u> | L5 and ((quiescent adj cell) or progenitor or (stem adj cell)) | 91 | <u>L6</u> |
| <u>L5</u> | L4 and L2 | 111 | <u>L5</u> |
| <u>L4</u> | (chimeric or fusion) same (cytokine or (growth adj factor) or interleukin) | 10025 | <u>L4</u> |
| <u>L3</u> | L2 same ((growth adj factor)or cytokine or interleukin) | 21 | <u>L3</u> |
| <u>L2</u> | (retroviral adj packaging) adj cell | 515 | <u>L2</u> |
| <u>L1</u> | Russell-Stephen-James.in. | 31 | <u>L1</u> |

END OF SEARCH HISTORY

Welcome to DialogClassic Web(tm)

Dialog level 05.06.01D
Last logoff: 25aug05 14:43:31
Logon file001 29aug05 14:57:44

*** ANNOUNCEMENT ***

--UPDATED: Important Notice to Freelance Authors--
See HELP FREELANCE for more information

NEW FILES RELEASED

***Computer and Information Systems Abstracts (File 56)
***Electronics and Communicationss Abstracts (File 57)
***Solid State and Superconductivity Abstracts (File 68)
***ANTE: Abstracts in New Technologies (File 60)
***Civil Engineering Abstracts (File 61)
***Aluminium Industry Abstracts (File 33)
***Ceramic Abstracts/World Ceramic Abstracts (File 335)
***CSA Life Sciences Abstracts (File 24)
***Corrosion Abstracts (File 46)
***Materials Business File (File 269)
***Engineered Materials Abstracts (File 293)
***CSA Aerospace & High Technology Database (File 108)
***CSA Technology Research Database (File 23)
***METADEX(r) (File 32)
***FDAnews (File 182)
***German Patents Fulltext (File 324) ***

RESUMED UPDATING

***Canadian Business and Current Affairs (262)
***CorpTech (559)

Chemical Structure Searching now available in Prous Science Drugs
of the Future (F453), IMS R&D Focus (F445), Beilstein Facts (F390),
and Derwent Chemistry Resource (F355).

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
>>> of new databases, price changes, etc. <<<

KWIC is set to 50.

HILIGHT set on as ' '

* * *

File 1:ERIC 1966-2004/Jul 21
(c) format only 2004 Dialog
*File 1: Updates suspended by ERIC until
Q3, 2005

| Set | Items | Description |
|-----|-------|-------------|
|-----|-------|-------------|

| | | |
|-----|-------|-------|
| --- | ----- | ----- |
|-----|-------|-------|

Cost is in DialUnits

?

B 155, 5, 73

29aug05 14:58:02 User259876 Session D787.1

\$0.80 0.228 DialUnits File1

\$0.80 Estimated cost File1

\$0.06 INTERNET

\$0.86 Estimated cost this search

\$0.86 Estimated total session cost 0.228 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1951-2005/Aug W4
 (c) format only 2005 Dialog
 File 5:Biosis Previews(R) 1969-2005/Aug W3
 (c) 2005 BIOSIS
 File 73:EMBASE 1974-2005/Aug 29
 (c) 2005 Elsevier Science B.V.

| Set | Items | Description |
|-----|-------|-------------|
| --- | ----- | ----- |

?

S (RETROVIRAL (W) PACKAGING (W) CELL?)
 Processing

| | | |
|----|---------|--------------------------------------|
| | 40981 | RETROVIRAL |
| | 34176 | PACKAGING |
| | 9678543 | CELL? |
| S1 | 175 | (RETROVIRAL (W) PACKAGING (W) CELL?) |

?

S (CHIMERIC OR FUSION) (S) (CYTOKINE OR (GROWTH (W) FACTOR) OR INTERLEUKIN)

| | | |
|----|---------|---|
| | 66535 | CHIMERIC |
| | 291217 | FUSION |
| | 274436 | CYTOKINE |
| | 2363401 | GROWTH |
| | 2369300 | FACTOR |
| | 494584 | GROWTH(W) FACTOR |
| | 479015 | INTERLEUKIN |
| S2 | 15236 | (CHIMERIC OR FUSION) (S) (CYTOKINE OR (GROWTH (W) FACTOR) OR INTERLEUKIN) |

?

S S1 AND S2

| | | |
|----|-------|-----------|
| | 175 | S1 |
| | 15236 | S2 |
| S3 | 2 | S1 AND S2 |

?

RD

...completed examining records
 S4 2 RD (unique items)

?

T S4/3,K/ALL

4/3,K/1 (Item 1 from file: 155)
 DIALOG(R) File 155:MEDLINE(R)
 (c) format only 2005 Dialog. All rts. reserv.

14911728 PMID: 12899748

[Treatment of hepatocellular carcinoma by transfecting interleukin -12 and interleukin -2 fusion gene intrasplenically, an experimental study]
 Yang Jia-he; Fan Rui-fang; Qian Qi-jun; You Tian-geng; Xue Hui-bin; Su Chang-qing; Cao Hui-fang; Wu Meng-chao
 Eastern Hepatobilliary Surgery Hospital, Second Military Medical University Shanghai 200438, China.
 Zhonghua yi xue za zhi (China) May 10 2003, 83 (9) p740-3, ISSN 0376-2491 Journal Code: 7511141
 Publishing Model Print
 Document type: Journal Article ; English Abstract
 Languages: CHINESE

Main Citation Owner: NLM
Record type: MEDLINE; Completed

[Treatment of hepatocellular carcinoma by transfecting interleukin -12 and interleukin -2 fusion gene intrasplenically, an experimental study]□
OBJECTIVE: To study the inhibitory effect of **retroviral packaging cells** injected intrasplenically encoding mouse **interleukin -12 (mIL-12)** and human **interleukin -2 (hIL-2)** **fusion** gene on the growth of hepatocellular carcinoma. METHODS: The retroviral vectors encoding mIL-12 gene, hIL-2 gene, and mIL-12 and hIL-2 genes, GCIL12EXP, GCXEIL2PN, and GCIL12EIL2PN were constructed and then transfected into the **retroviral packaging cells** PA317 to construct cells PA317-GCIL12EXP, PA317-GCXEIL2PN, and PA317-GCIL12EIL2PN. Rat hepatocellular carcinoma cells CBRH3 were implanted into the livers of Wistar rats to...

...10(7) cells/rat 1, 3, 5, or 7 days after the implantation, group IV, n = 40), and PA317-GCIL12EIL2PN containing IL-12-IL-2 **fusion** gene (1 x 10(7) cells/rat 1, 3, 5, or 7 days after the implantation, group V, n = 40) respectively. The rats surviving longer...

... day before and 3, 7, 30, and 60 days after treatment. RESULTS: The average survival times of the rats treated with IL-12-IL-2 **fusion** gene at the first, third, fifth and seventh day after tumor implantation were 53.3 +/- 3.7 days, 49.3 +/- 4.2 days, 31.0...

... and 19.4 +/- 2.1 days respectively, P < 0.001). Long survival (>or= 60 days) rate in the rats treated with IL-12-IL-2 **fusion** gene on the first and third day was 30%. The serum mIL-12 and hIL-2 levels in these rats remained high on the 60th day after treatment. The pathological study showed that the number of infiltrating lymphocytes in liver tumor tissues was increased in the IL-12-IL-2 **fusion** gene treatment group. CONCLUSION: The **retroviral packaging cell** line injected intrasplenically encoding mIL-12 and hIL-2 **fusion** gene inhibits the growth of hepatocellular carcinoma significantly in rats. The therapeutical efficacy of early administration is superior to that of late one.

4/3,K/2 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0014887161 BIOSIS NO.: 200400257918

Materials and methods relating to the transfer of nucleic acid into quiescent cells

AUTHOR: Russell Stephen James (Reprint); Fielding Adele Kay; Casimir Colin Maurice

AUTHOR ADDRESS: Cambridge, UK**UK

JOURNAL: Official Gazette of the United States Patent and Trademark Office
Patents 1281 (3): Apr. 20, 2004 2004

MEDIUM: e-file

PATENT NUMBER: US 6723561 PATENT DATE GRANTED: April 20, 2004 20040420

PATENT CLASSIFICATION: 435-377 PATENT ASSIGNEE: Mayo Foundation for
Medical Education and Research PATENT COUNTRY: USA

ISSN: 0098-1133 (ISSN print)

DOCUMENT TYPE: Patent

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: for transferring nucleic acid encoding a polypeptide for
treating a disease or disorder into populations of quiescent cells such

as haematopoietic stem cells (HSCs), using **retroviral packaging cell** lines and retroviral particles expressing and display a growth factor such as stem cell factor (SCF) on the cell surface or as a **fusion** with a viral envelope protein. The present invention also relates to compositions comprising the **retroviral packaging cell** lines and retroviral particles, and their use in methods of medical treatment, in vivo and ex vivo.

?

| Set | Items | Description |
|-----|-------|---|
| S1 | 175 | (RETROVIRAL (W) PACKAGING (W) CELL?) |
| S2 | 15236 | (CHIMERIC OR FUSION) (S) (CYTOKINE OR (GROWTH (W) FACTOR) - OR INTERLEUKIN) |
| S3 | 2 | S1 AND S2 |
| S4 | 2 | RD (unique items) |

?

S (QUIESCENT (W) CELL?) OR PROGENITOR? OR (STEM (W) CELL?)

Processing

Processing

| | | |
|----|---------|--|
| | 34533 | QUIESCENT |
| | 9678543 | CELL? |
| | 6133 | QUIESCENT (W) CELL? |
| | 100384 | PROGENITOR? |
| | 381602 | STEM |
| | 9678543 | CELL? |
| | 199635 | STEM (W) CELL? |
| S5 | 263991 | (QUIESCENT (W) CELL?) OR PROGENITOR? OR (STEM (W) CELL?) |

?

| Set | Items | Description |
|-----|--------|---|
| S1 | 175 | (RETROVIRAL (W) PACKAGING (W) CELL?) |
| S2 | 15236 | (CHIMERIC OR FUSION) (S) (CYTOKINE OR (GROWTH (W) FACTOR) - OR INTERLEUKIN) |
| S3 | 2 | S1 AND S2 |
| S4 | 2 | RD (unique items) |
| S5 | 263991 | (QUIESCENT (W) CELL?) OR PROGENITOR? OR (STEM (W) CELL?) |

?

S S1 AND S5

| | | |
|----|--------|-----------|
| | 175 | S1 |
| | 263991 | S5 |
| S6 | 28 | S1 AND S5 |

?

S S6 AND (CYTOKINE? OR (GROWTH (W) FACTOR?) OR INTERLEUKIN? OR SCF

>>>Unmatched parentheses

?

S S6 AND (CYTOKINE? OR (GROWTH (W) FACTOR?) OR INTERLEUKIN? OR SCF)

| | | |
|----|---------|---|
| | 28 | S6 |
| | 401516 | CYTOKINE? |
| | 2363401 | GROWTH |
| | 4824092 | FACTOR? |
| | 544380 | GROWTH (W) FACTOR? |
| | 483512 | INTERLEUKIN? |
| | 10620 | SCF |
| S7 | 8 | S6 AND (CYTOKINE? OR (GROWTH (W) FACTOR?) OR INTERLEUKIN? |

OR SCF)

?

RD

...completed examining records
S8 5 RD (unique items)

?

T S8/3,K/ALL

8/3,K/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

16241074 PMID: 15468194

Growth factor displayed on the surface of retroviral particles without manipulation of envelope proteins is biologically active and can enhance transduction.

Chandrashekran Anil; Gordon Myrtle Y; Darling David; Farzaneh Farzin; Casimir Colin

Department of Haematology, Faculty of Medicine, Imperial College of Science Technology & Medicine, Du Cane Road, London W12 0NN, UK.

Journal of gene medicine (England) Nov 2004, 6 (11) p1189-96, ISSN 1099-498X Journal Code: 9815764

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: In Process

Growth factor displayed on the surface of retroviral particles without manipulation of envelope proteins is biologically active and can enhance transduction.

... report we have tested whether the natural budding mechanism of the retrovirus could be exploited to incorporate a specific molecule into the retroviral surface. METHODS: Retroviral packaging cells were engineered to express the membrane-bound form of human stem cell factor (mbSCF). Surface expression of mbSCF on retroviral packaging cells was confirmed by immunofluorescence and flow cytometry. Incorporation of mbSCF into retroviral particles was demonstrated by virus-binding assay and immunomagnetic capture of virus using antibody to SCF. Retroviral supernatants were tested for activity of the incorporated cytokine by proliferation assays on factor-dependent cells. Amphotropic retrovirus displaying surface mbSCF was used to transduce SCF receptor-positive haematopoietic cells. RESULTS: Retroviruses incorporating surface SCF showed increased levels of binding to cells (MO7e) expressing the SCF receptor, c-kit. mbSCF displayed on the viral surface retained levels of biological activity comparable with those of soluble recombinant growth factor. Transduction of c-kit-positive target cells with viruses displaying mbSCF showed enhanced levels of transduction in comparison with unmodified viruses. CONCLUSIONS: Expression of the membrane-bound form of human stem cell factor (mbSCF) on the surface of retroviral packaging cells allows its efficient incorporation into retrovirus particles in a biologically active form, opening up the possibility for the use of retroviral display in many therapeutic...

8/3,K/2 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

12849549 PMID: 10791900

Distinct effect of retroviral-mediated IFN-alpha gene transfer on human erythroleukemic and CD34+ cell growth and differentiation.

Quan S; Feldman E; Yang L; Wagener F A; Farley T J; Abraham N G; Ahmed T
Department of Pharmacology, Saint Vincent Hospital, New York Medical
College, Valhalla 10595, USA.

Journal of hematotherapy & stem cell research (UNITED STATES) Oct 1999,
8 (5) p491-502, ISSN 1525-8165 Journal Code: 100892915

Contract/Grant No.: HL54138; HL; NHLBI

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

...and LNC-IFN-alpha, in which IFN-alpha cDNA was driven by viral LTR and CMV promoters, respectively. After transduction into the PA317 and PG13 retroviral packaging cells, high titers of retrovirus were produced and were used to infect K562 and human BM CD34+ hematopoietic cells. The IFN-alpha gene expression in transduced...

... of IFN-alpha gene transfer on human CD34+ cells infected with LSN-IFN-alpha retrovirus with the aid of fibronectin (FN) fragment CH-296 and growth factors. RIA showed that IFN-alpha-transduced CD34+ cells produced 72.2+/-15 U/ml of IFN-alpha compared with 4.3+/-1.2 U/ml...

Descriptors: *Bone Marrow Cells--cytology--CY; *Cell Differentiation; *Gene Transfer Techniques; *Hematopoietic Stem Cells --cytology--CY; *Interferon-alpha--genetics--GE

8/3,K/3 (Item 3 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

12526077 PMID: 9834203

Highly efficient transduction of the green fluorescent protein gene in human umbilical cord blood stem cells capable of cobblestone formation in long-term cultures and multilineage engraftment of immunodeficient mice.

van Hennik P B; Verstegen M M; Bierhuizen M F; Limon A; Wognum A W; Cancelas J A; Barquinero J; Ploemacher R E; Wagemaker G

Institute of Hematology, Erasmus University Rotterdam, The Netherlands; and the Department of Cryobiology and Cell Therapy, Institut de Recerca Oncologica, Barcelona, Spain.

Blood (UNITED STATES) Dec 1 1998, 92 (11) p4013-22, ISSN 0006-4971
Journal Code: 7603509

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Highly efficient transduction of the green fluorescent protein gene in human umbilical cord blood stem cells capable of cobblestone formation in long-term cultures and multilineage engraftment of immunodeficient mice.

... or with SF-EGFP, in which EGFP expression is driven by a hybrid promoter of the spleen focus-forming virus (SFFV) and the murine embryonic stem cell virus (MESV). Infectious MFG-EGFP virus was produced by an amphotropic virus producer cell line (GP+envAml2). SF-EGFP was produced in the PG13 cell line pseudotyped for the gibbon ape leukemia virus (GaLV) envelope proteins. Using a 2-day growth factor prestimulation, followed

by a 2-day, fibronectin fragment CH-296-supported transduction, CD34(+) and CD34(+)CD38(-) UCB subsets were efficiently transduced using either vector. The use of the SF-EGFP/PGL3 **retroviral packaging cell** combination consistently resulted in twofold higher levels of EGFP-expressing cells than the MFG-EGFP/Aml2 combination. Transplantation of 10(5) input equivalent transduced CD34...

...that the NOD/SCID repopulating cells were successfully transduced. EGFP+ cells were found in all human hematopoietic lineages produced in NOD/SCID mice including human **progenitors** with in vitro clonogenic ability. EGFP-expressing cells were also detected in the human cobblestone area-forming cell (CAFC) assay at 2 to 6 weeks...

...cell line FBMD-1. During the transduction procedure the absolute numbers of CAFC week 6 increased 5- to 10-fold. The transduction efficiency of this **progenitor** cell subset was similar to the fraction of EGFP+ human cells in the bone marrow of the NOD/SCID mice transplanted with MFG-EGFP/Aml2...

Descriptors: *Gene Transfer Techniques; *Hematopoietic **Stem Cell** Transplantation; *Hematopoietic **Stem Cells** --physiology--PH; *Luminescent Proteins--genetics--GE; Animals; Cell Differentiation; Cells, Cultured; Colony-Forming Units Assay--methods--MT; Fetal Blood--cytology--CY; Graft Survival; Hematopoietic **Stem Cells** --cytology--CY; Humans; Mice; Mice, SCID

8/3,K/4 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0014887161 BIOSIS NO.: 200400257918

Materials and methods relating to the transfer of nucleic acid into quiescent cells

AUTHOR: Russell Stephen James (Reprint); Fielding Adele Kay; Casimir Colin Maurice

AUTHOR ADDRESS: Cambridge, UK**UK

JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1281 (3): Apr. 20, 2004 2004

MEDIUM: e-file

PATENT NUMBER: US 6723561 PATENT DATE GRANTED: April 20, 2004 20040420

PATENT CLASSIFICATION: 435-377 PATENT ASSIGNEE: Mayo Foundation for Medical Education and Research PATENT COUNTRY: USA

ISSN: 0098-1133 (ISSN print)

DOCUMENT TYPE: Patent

RECORD TYPE: Abstract

LANGUAGE: English

Materials and methods relating to the transfer of nucleic acid into quiescent cells

ABSTRACT: Materials and methods for transferring nucleic acid encoding a polypeptide for treating a disease or disorder into populations of **quiescent cells** such as haematopoietic **stem cells** (HSCs), using **retroviral packaging cell** lines and retroviral particles expressing and display a **growth factor** such as **stem cell factor** (SCF) on the cell surface or as a fusion with a viral envelope protein. The present invention also relates to compositions comprising the **retroviral packaging cell** lines and retroviral particles, and their use in methods of medical treatment, in vivo and ex vivo.

DESCRIPTORS:

ORGANISMS: PARTS ETC: hematopoietic **stem cells** --....

... **quiescent cells**
 CHEMICALS & BIOCHEMICALS: ... **stem cell factor**

8/3,K/5 (Item 2 from file: 5)
 DIALOG(R)File 5:Biosis Previews(R)
 (c) 2005 BIOSIS. All rts. reserv.

0013563981 BIOSIS NO.: 200200157492

Establishment of a stable RD114 retroviral packaging cell line that efficiently transduces human hematopoietic progenitors

AUTHOR: Ward Maureen; Sattler Rose; Baxi Laxmi; Reyngold Marcia; Bank Arthur (Reprint)

AUTHOR ADDRESS: Medicine, Columbia U., New York City, NY, USA**USA

JOURNAL: Blood 98 (11 Part 2): p408b November 16, 2001 2001

MEDIUM: print

CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 2 Orlando, Florida, USA December 07-11, 2001; 20011207

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

Establishment of a stable RD114 retroviral packaging cell line that efficiently transduces human hematopoietic progenitors

ABSTRACT: The RD114 feline endogenous virus envelope (env) has been reported to transfer and express GFP into human hematopoietic **stem cells** (HSC) at a high level as assessed in NOD-SCID mice (Kelly et al Blood 96:1206, 2000)). In these studies, transient packaging systems in

...

...envAml2 line (Ampho-Neo). CD34+ cord blood cells were isolated by negative selection, transduced on Retronectin in serum-free media (IMDM, 20% BIT) and with **growth factors** (IL-6, FLT3 ligand, G-CSF, **SCF**, and TPO). PCR analysis of methylcellulose colonies from transduced cells showed 10-20% of the colonies positive for NeoR in different experiments. These results suggest...

DESCRIPTORS:

...ORGANISMS: PARTS ETC: hematopoietic **stem cell** --
 ?

| Set | Items | Description |
|-----|--------|---|
| S1 | 175 | (RETROVIRAL (W) PACKAGING (W) CELL?) |
| S2 | 15236 | (CHIMERIC OR FUSION) (S) (CYTOKINE OR (GROWTH (W) FACTOR) - OR INTERLEUKIN) |
| S3 | 2 | S1 AND S2 |
| S4 | 2 | RD (unique items) |
| S5 | 263991 | (QUIESCENT (W) CELL?) OR PROGENITOR? OR (STEM (W) CELL?) |
| S6 | 28 | S1 AND S5 |
| S7 | 8 | S6 AND (CYTOKINE? OR (GROWTH (W) FACTOR?) OR INTERLEUKIN? - OR SCF) |
| S8 | 5 | RD (unique items) |
| ? | | |

Set Items Description

S1 175 (RETROVIRAL (W) PACKAGING (W) CELL?)
S2 15236 (CHIMERIC OR FUSION) (S) (CYTOKINE OR (GROWTH (W) FACTOR) -
OR INTERLEUKIN)
S3 2 S1 AND S2
S4 2 RD (unique items)
S5 263991 (QUIESCENT (W) CELL?) OR PROGENITOR? OR (STEM (W) CELL?)
S6 28 S1 AND S5
S7 8 S6 AND (CYTOKINE? OR (GROWTH (W) FACTOR?) OR INTERLEUKIN? -
OR SCF)
S8 5 RD (unique items)
?

COST

29aug05 15:05:56 User259876 Session D787.2
\$7.51 2.208 DialUnits File155
\$0.84 4 Type(s) in Format 3
\$0.84 4 Types
\$8.35 Estimated cost File155
\$15.11 2.562 DialUnits File5
\$4.00 2 Type(s) in Format 3
\$0.16 1 Type(s) in Format 95 (KWIC)
\$4.16 3 Types
\$19.27 Estimated cost File5
\$21.62 2.034 DialUnits File73
\$21.62 Estimated cost File73
OneSearch, 3 files, 6.803 DialUnits FileOS
\$2.13 INTERNET
\$51.37 Estimated cost this search
\$52.23 Estimated total session cost 7.032 DialUnits

?

Return to logon page!



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



PALM INTRANET

Day : Monday
Date: 8/29/2005

Time: 15:33:50

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)